Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 199Breast Neoplasms 136Prostatic Neoplasms 72Neoplasms 62Neoplasm Metastasis 52Lung Neoplasms 45Stomach Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 22Squamous Cell Carcinoma of Head and Neck 17Ovarian Neoplasms 15Advanced Solid Tumors 14Recurrence 12Head and Neck Neoplasms 11Colorectal Neoplasms 11Carcinoma, Squamous Cell 11Urinary Bladder Neoplasms 10Melanoma 10Esophageal Neoplasms 10HER2-positive Breast Cancer 9Endometrial Neoplasms 9Carcinoma, Renal Cell 9Sarcoma 8Esophageal Squamous Cell Carcinoma 8Carcinoma, Transitional Cell 8Solid Tumor 7Prostatic Neoplasms, Castration-Resistant 7Pancreatic Neoplasms 7Carcinoma 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6

Interventions

pegfilgrastim 7NPI 2358 4Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Docetaxel 3balugrastim 2Drug Therapy 2Cyclophosphamide 2pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Chemotherapy-induced Neutropenia × Docetaxel × Clear all
NCT01126190 2023-03-28

NEUGR-003

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed
381 enrolled 13 charts

Chemotherapy-induced Neutropenia

NCT03294577 2021-01-15

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 3 Unknown
221 enrolled

Chemotherapy-induced Neutropenia

NCT04227990 2020-01-18

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

BeyondSpring Pharmaceuticals Inc.

Phase 2 Completed
115 enrolled

Chemotherapy-induced Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡